|Bid||79.1200 x 800|
|Ask||79.1300 x 900|
|Day's range||77.6100 - 79.1799|
|52-week range||60.1400 - 84.0000|
|PE ratio (TTM)||26.88|
|Earnings date||6 Nov 2018|
|Forward dividend & yield||2.00 (2.60%)|
|1y target est||86.10|
Wall Street analysts estimate that DaVita (DVA) will report a 25.3% decline in revenues to $11.6 billion in 2018 compared to $15.5 billion in 2017. Its adjusted EPS is estimated at $4 in 2018 compared to $3.32 in 2017. Analysts estimate that its net adjusted income will increase to $693.4 million in 2018 compared to $634.9 million in 2017.
A robust 2019 PBM selling season is a tailwind for CVS Health (CVS). Additionally, the company's milestone acquisition of Aetna might alter the whole healthcare landscape in the United States.
I am going to run you through how I calculated the intrinsic value of CVS Health Corporation (NYSE:CVS) by projecting its future cash flows and then discounting them to today’sRead More...
NEW YORK, Aug. 31, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of General ...
Considering the rising popularity of PBM, CRO and EHR in the U.S. Medical Services industry, these three picks might be money-spinning choices for investors.
This analysis is intended to introduce important early concepts to people who are starting to invest and want to begin learning about how to value company based on its currentRead More...
A solid 2019 PBM selling season is a significant positive for CVS Health's (CVS) growth. The company completes more than 70% of its client renewals, almost in line with the prior-year level.
CVS Health (CVS) released its second-quarter results on August 8 before the market opened. The company’s revenues for the quarter grew 2.2% YoY (year-over-year) to $46.7 billion and beat the estimate by 0.8%. CVS Health’s earnings increased 27.1% YoY to $1.6 per share and exceeded the forecast of $1.6 per share.
So far, 91% of the companies in the S&P 500 have reported their third-quarter earnings. Last week was mediocre for the market. The S&P 500 Index (SPY) fell 0.25% for the week ending August 10. Last week was average for most of the sectors in the index.
CVS Health’s (CVS) better-than-expected second-quarter results managed to please investors. The company’s share price soared 6% during the day on August 8 before finally settling at $68.17, 4.2% higher than the previous day’s close.
As discussed in the previous section, six analysts have downgraded Walgreens Boots Alliance (WBA) since Amazon’s (AMZN) acquisition of PillPack in late June. As a result, Walgreens’s overall ratings have come down drastically. The company, which was rated 2.3 before the acquisition on June 28, is now ranked as a 2.7. Ratings are on a scale where one is a “strong buy,” and five is a “strong sell.”
CVS Health (CVS) once again cruised ahead of bottom line expectations when it reported its second-quarter results yesterday morning. Its adjusted EPS rose 27.1% YoY (year-over-year) to $1.69, $0.08 more than the Thomson Reuters I/B/E/S estimate. This was the tenth consecutive earnings beat for the company.
CVS Health (CVS) posted better-than-expected quarterly sales when it reported its second-quarter results on August 8. Its top line improved 2.2% YoY (year-over-year) to $46.7 billion.
Some Rite Aid stockholders were apparently unwilling to approve the pharmacy chain's merger with grocer Albertsons in a vote scheduled Thursday, so on Wednesday night, Rite Aid and Albertsons called off the merger. Rite Aid's balky shareholders may rue their opposition to the deal. In heavy trading, Rite Aid (RAD) stock was down about 10% early Thursday afternoon, to just $1.56 a share. Pharmacies are in the thick of the transformation of the health care economy. CVS Health (CVS) wants to merge with insurer Aetna (AET), while benefits manager Express Scripts Holdings (ESRX) aims to join insurer Cigna (CI).
CVS Health (CVS) reported its second-quarter earnings results on August 8. The pharmacy giant reported better-than-expected top and bottom line results during the quarter.
Walgreens Boots Alliance (WBA) stock has been in the red almost throughout the whole year so far. Interestingly, the pharmacy giant’s stock performance hasn’t been driven by its own financial performance, but by Amazon’s expansion plans in the pharma space. Walgreens has reported quarterly results for the first three fiscal quarters of 2018 this year.